Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


House Wants FDA Action On Non-Pharma Pain Relievers, Breast Density Reports, Pediatric Devices In 2020

Executive Summary

The US House Appropriations Committee wants the FDA to foster development of non-pharma and non-opioid pain alternatives, complete mammography breast density reporting regulations, and use an additional $1m Congress would provide to conduct pediatric device trials, among other device initiatives outlined in its 2020 budget bill passed on 4 June.

You may also be interested in...

Raise In Debt Ceiling Means FDA Funding Bill Can Advance

The US House on 25 July signed off on a two-year budget deal for FY 2020 and 2021 raising the federal debt ceiling, and allowing funding for FDA and other federal agencies to go forward.

US House Passes FDA 2020 Budget In Minibus Bill, Moving It To Senate After $5M Boost In Telemedicine Funds

US appropriations legislation that would give the FDA’s device center an 8% raise over last year was passed by the US House on 25 June as part of a five-bill “minibus” package. It will move to the Senate for consideration after the US Independence Day recess. Among the last-minute amendments to H.R. 3055 was a $5m boost for telemedicine.

US House Agrees To Retain 8% Boost In Funding For FDA's Device Center Next Year

The US House completed work on the FDA portion of an appropriations “minibus” bill for 2020 on 20 June, agreeing to retain an approximate 8% increase for the agency’s device center.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts